Department of Dermatology, University of Michigan, Ann Arbor, Michigan.
Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Clin Cancer Res. 2021 May 1;27(9):2494-2504. doi: 10.1158/1078-0432.CCR-20-0864. Epub 2021 Feb 5.
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma that can be divided into two classes: virus-positive (VP) MCC, associated with oncogenic Merkel cell polyomavirus (MCPyV); and virus-negative (VN) MCC, associated with photodamage.
We classified 346 MCC tumors from 300 patients for MCPyV using a combination of IHC, ISH, and qPCR assays. In a subset of tumors, we profiled mutation status and expression of cancer-relevant genes. MCPyV and molecular profiling results were correlated with disease-specific outcomes. Potential prognostic biomarkers were further validated by IHC.
A total of 177 tumors were classified as VP-MCC, 151 tumors were VN-MCC, and 17 tumors were indeterminate. MCPyV positivity in primary tumors was associated with longer disease-specific and recurrence-free survival in univariate analysis, and in multivariate analysis incorporating age, sex, immune status, and stage at presentation. Prioritized oncogene or tumor suppressor mutations were frequent in VN-MCC but rare in VP-MCC. mutation developed with recurrence in one VP-MCC case. Importantly, for the first time we find that VP-MCC and VN-MCC display distinct sets of prognostic molecular biomarkers. For VP-MCC, shorter survival was associated with decreased expression of immune markers including granzyme and IDO1. For VN-MCC, shorter survival correlated with high expression of several genes including .
MCPyV status is an independent prognostic factor for MCC. Features of the tumor genome, transcriptome, and microenvironment may modify prognosis in a manner specific to viral status. MCPyV status has clinicopathologic significance and allows for identification of additional prognostic subgroups.
默克尔细胞癌(MCC)是一种侵袭性皮肤神经内分泌癌,可分为两类:病毒阳性(VP)MCC,与致癌性默克尔细胞多瘤病毒(MCPyV)相关;以及病毒阴性(VN)MCC,与光损伤相关。
我们使用 IHC、ISH 和 qPCR 组合检测 300 例患者的 346 例 MCC 肿瘤中的 MCPyV。在肿瘤的亚组中,我们分析了突变状态和与癌症相关基因的表达。MCPyV 和分子分析结果与疾病特异性结果相关。通过 IHC 进一步验证潜在的预后生物标志物。
共有 177 例肿瘤被归类为 VP-MCC,151 例肿瘤为 VN-MCC,17 例肿瘤为不确定。原发性肿瘤中 MCPyV 的阳性与单因素分析中的疾病特异性和无复发生存期延长相关,多因素分析纳入年龄、性别、免疫状态和初诊时的分期。VN-MCC 中频繁出现优先致癌基因或肿瘤抑制基因的突变,但 VP-MCC 中罕见。在一个 VP-MCC 病例中,随着复发出现了 突变。重要的是,我们首次发现 VP-MCC 和 VN-MCC 显示出不同的预后分子生物标志物。对于 VP-MCC,免疫标志物包括颗粒酶和 IDO1 的表达降低与较短的生存时间相关。对于 VN-MCC,较短的生存时间与包括 在内的多个基因的高表达相关。
MCPyV 状态是 MCC 的独立预后因素。肿瘤基因组、转录组和微环境的特征可能以特定于病毒状态的方式改变预后。MCPyV 状态具有临床病理意义,并可识别其他预后亚组。